A Phase 3 interventional study of Fluticasone furoate/Vilanterol Inhalation Powder and Fluticasone Furoate Inhalation Powder in Asthma, sponsored by GlaxoSmithKline. Completed at 70 sites in 6 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-02-14.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 262 studies in Asthma by GlaxoSmithKline — 7 open to participants now, 12 under way, 7 of them phase 3. Asthma · GlaxoSmithKline.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 30th largest by enrollment of the 238 interventional ones that give a count, is one of 34 that started in 2010, is one of 61 in phase 3, and was the 102nd registered.
4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.
Browse Asthma studies →7 of the 262 studies in Asthma by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States, Argentina, Canada and 1 more country
Ages 18+
GlaxoSmithKline · Sites in United States
Ages 12–80
GlaxoSmithKline · Sites in United States, Japan
Ages 12–80
GlaxoSmithKline · Sites in United States
Ages 6–11
GlaxoSmithKline · Sites in United States, United Kingdom
Ages 12+
By country, each count listing its studies:
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
262 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 63 · Phase 2 60 · Phase 3 61 · Phase 4 53
First in 1999; this study’s year is marked. 34 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 612 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 93 across the 238 interventional studies, 512 across the 24 observational. Of the 240 that completed or were terminated, 132 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
5 of the studies in Asthma by GlaxoSmithKline that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07645248Phase 3GlaxoSmithKlineA Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a) | 2026-12-28 |
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT07671001Phase 3GlaxoSmithKlineA Study of Depemokimab in Participants of 6 to 11 Years of Age | 2027-03-01 |
| NCT07712393GlaxoSmithKlineA Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of GSK5784283 | 2027-04-13 |
| NCT06433921GlaxoSmithKlineA Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive | 2027-04-16 |
Add all 5 to your calendar (.ics) → With an account.
Among the 262 studies in Asthma by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder and fluticasone furoate inhalation powder both administered once daily in adolescent and adult subjects 12 years of age and older with persistent bronchial asthma over a 12 week treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fluticasone furoate/Vilanterol inhalation powder once daily for 12 weeks
Drug: Fluticasone furoate/Vilanterol Inhalation Powder
Fluticasone furoate inhalation powder once daily for 12 weeks
Drug: Fluticasone Furoate Inhalation Powder
Placebo inhalation powder once daily for 12 weeks
Drug: Placebo Inhaltion Powder
Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 12 weeks
Fluticasone Furoate Inhalation Powder inhaled orally once daily for 12 weeks
Placebo Inhaltion Powder inhaled orally once daily for 12 weeks
Mean Change From Baseline in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at Week 12
Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 is defined as the clinic visit (pre-bronchodilator and pre-dose) FEV1measurement taken at the clinic visit while still on-treatment. Pre-dose and pre-rescue albuterol/salbutamol trough FEV1 was measured electronically by spirometry in the evening at the Baseline through Week 12 clinic visits. The highest of 3 technically acceptable measurements was recorded. Baseline was the pre-dose value obtained at Visit 3. Change from Baseline was calculated as the Week 12 value minus the Baseline value. The analysis was performed using an Analysis of Covariance (ANCOVA) model with covariates of Baseline trough FEV1, region, sex, age, and treatment group. The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement at scheduled clinic visits was used to impute the missing m
Time frame: Baseline and Week 12
Change From Baseline in Weighted Mean Serial FEV1 Over 0-24 Hours Post-dose at Week 12
Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Serial FEV1 measurements were taken electronically by spirometry at the Baseline and Week 12 clinic visits. Weighted mean was calculated using the 24-hour serial FEV1 measurements that included the pre-dose assessment (within 30 minutes prior to dosing at Baseline and within 5 minutes prior to dosing at Week 12) and post-dose assessments after 5, 15, and 30 minutes and 1, 2, 3, 4, 5, 12, 16, 20, 23, and 24 hours. At each time point, the highest of 3 technically acceptable measurements was recorded. Baseline was the value obtained at Visit 3. Change from Baseline was calculated as the average Week 12 FEV1 value minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline FEV1, region, sex, age, and treatment group.
Time frame: Baseline and Week 12
Mean Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 12-week Treatment Period
The number of inhalations of rescue albuterol/salbutamol inhalation aerosol used during the day and night was recorded by the participants in a daily electronic diary (eDiary). A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered to be rescue free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 12-week Treatment Period minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.
Time frame: Baseline and Week 12
Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 12-week Treatment Period
Asthma symptoms were recorded in a daily eDairy by the participants every day in the morning and evening before taking any rescue or study medication and before the peak expiratory flow measurement. A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered to be symptom free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 12-week Treatment Period minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.
Time frame: Baseline and Week 12
Change From Baseline in the Total Asthma Quality of Life Questionnaire (AQLQ) (+12) Score at Week 12/Early Withdrawal
The AQLQ is a disease-specific, self-administered quality of life questionnaire used to evaluate the impact of asthma treatments on the quality of life of asthma sufferers. The AQLQ for 12 years and older (AQLQ \[+12\]) is a modified version of the AQLQ for use in asthma patients between the age of 12 and 70. The AQLQ contains 32 items in 4 domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), and environmental stimuli (4 items). For the 32 items on the questionnaire, the response format consists of a seven-point scale, where a value of 1 indicates "total impairment" and a value of 7 indicates "no impairment." The AQLQ total score is defined as the average of the scores from all 32 questions; thus, the total score ranges from 1 (indicates "total impairment") to 7 (indicates "no impairment"). Baseline was the total score obtained at Visit 3. Change from Baseline was calculated as the total score at Week 12 minus the total score at Baseline.
Time frame: Baseline and Week 12/Early Withdrawal
Number of Participants Who Withdrew Due to Lack of Efficacy During the 12-week Treatment Period
The number of participants whose primary reason for withdrawal was lack of efficacy was analyzed.
Time frame: From the first dose of the study medication up to Week 12/Early Withdrawal
Serial FEV1 Over 0-1 Hour Post-dose at Randomization
Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Serial FEV1 measurements were taken electronically by spirometry at Randomization. Serial FEV1 measurements after 5, 15, and 30 minutes and 1 hour post-dose were assessed. At each time point, the highest of 3 technically acceptable measurements was recorded. The analysis was performed using a repeated measures model adjusted for baseline, region, sex, age, treatment group, and planned time points.
Time frame: Randomization
Clinic Visit 12-hour Post-dose FEV1 at Week 12
Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. 12-hour post-dose FEV1 measurements were taken electronically by spirometry at the Week 12 clinic visit. The highest of 3 technically acceptable measurements was recorded. The analysis was performed using an ANCOVA model with covariates of Baseline FEV1, region, sex, age, and treatment group.
Time frame: Week 12
Weighted Mean Serial FEV1 Over 0-24 Hours Post-dose at Baseline
Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Serial FEV1 measurements were taken electronically by spirometry at Baseline. Weighted mean was calculated using the 24-hour serial FEV1 measurements that included the pre-dose assessment (within 30 minutes prior to dosing) and post-dose assessments after 5, 15, and 30 minutes and 1, 2, 3, 4, 5, 12, 16, 20, 23, and 24 hours. At each time point, the highest of 3 technically acceptable measurements were recorded. Baseline was the value obtained at Visit 3.
Time frame: Baseline
Weighted Mean Serial FEV1 Over 0-4 Hours Post-dose at Baseline and Week 12
Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Serial FEV1 measurements were taken electronically by spirometry at the Baseline and Week 12 clinic visits. Weighted mean serial FEV1 over 0-4 hours was calculated using the serial FEV1 measurements that included the pre-dose assessment (within 30 minutes prior to dosing at Baseline and within 5 minutes prior to dosing at Week 12) and post-dose assessments after 5, 15, and 30 minutes and 1, 2, 3, and 4 hours. At each time point, the highest of 3 technically acceptable measurements were recorded. Baseline was the value obtained at Visit 3.
Time frame: Baseline and Week 12
Number of Participants With Bronchodilator Effect
Bronchodilator effect is defined as an increase of FEV1 (defined as the maximal amount of air that can be forcefully exhaled in one second) from Baseline of both 12% and 200 milliliters (mL) during 24 hours, which was evaluated using the serial FEV1 measurements at Baseline (Visit 3).
Time frame: Baseline
Mean Change From Baseline in Daily Morning (AM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period
Peak Expiratory Flow (PEF) is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each morning prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily AM PEF over the 12-week treatment period (at Week 12) minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.
Time frame: From Baseline up to Week 12
Mean Change From Baseline in Daily Evening (PM) PEF Averaged Over the 12-week Treatment Period
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily PM PEF over the 12-week treatment period (at Week 12) minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.
Time frame: From Baseline up to Week 12
Change From Baseline in the Asthma Control Test (ACT) Score at Week 12
The ACT is a 5-item questionnaire developed as a measure of the participant's asthma control. Questions are designed to be self-completed by the participant and include the following: In the past 4 weeks, "How much of the time did your asthma keep you from getting as much done at work, school or at home?", "How often have you had shortness of breath?", "How often did your asthma symptoms wake you up at night or earlier than usual in the morning?", "How often have you used your rescue inhaler or nebulizer medication (such as albuterol)?" and "How would you rate your asthma control"? The ACT total score is defined as the sum of the scores from all 5 questions, provided all questions have been answered; thus, the total score ranges from 5 (poor control of asthma) to 25 (complete control of asthma). A score of 20 or higher indicates well-controlled asthma. Change from Baseline was calculated as the total score at Week 12/Early Withdrawal minus the total score at Baseline.
Time frame: Baseline and Week 12/Early Withdrawal
Number of Participants With the Indicated Global Assessment of Change Responses at Week 4, Week 8, and Week 12/Early Withdrawal
At the end of Week 4, Week 8, and Week 12/Early Withdrawal, the Global Assessment of Change Questionnaire that assesses changes in asthma symptoms (AS) and rescue medication use (RMU) was completed by the participants. The number of participants who chose the following answers to the questionnaire were determined: much better, somewhat better, a little better, the same, a little worse, somewhat worse, much worse (to assess the changes in asthma symptom); much less often , somewhat less often , a little less often , the same , a little more often , somewhat more often , much more often (to assess the changes in the frequency of rescue medication use).
Time frame: Week 4, Week 8, and Week 12/Early Withdrawal
Number of the Indicated Unscheduled Asthma-related Healthcare Visits During the Treatment Period
All unscheduled asthma-related visits to a physician's office, visits to urgent care, visits to the emergency department, and hospitalizations (ICU=intensive care unit; GW=general ward) associated with severe asthma exacerbations or other asthma-related healthcare were recorded.
Time frame: From Baseline up to Week 12/Early Withdrawal
Number of Participants Who Used the Inhaler Correctly or Incorrectly at Baseline, Week 2, and Week 4
Participants were given a demonstration of correct inhaler use (using placebo inhalers), and the participants' competence to correctly use the demonstration inhaler was then assessed.
Time frame: Baseline (BL), Week 2 (W2), and Week 4 (W4)
Number of Participants With the Indicated Reason for Incorrect Inhaler Use and Who Required Additional Instruction the Indicated Number of Times at Baseline, Week 2, and Week 4
Participants were given a demonstration of correct inhaler use (using placebo inhalers), and the participants' competence to correctly use the demonstration inhaler was then assessed based on 3 steps: open the device, inhale the dose, and close the device. If the participants did not perform the maneuvers correctly, the step of the inhaler use that was performed incorrectly by the participants was recorded. The entire procedure was demonstrated once again. and the number of times that the participants required additional instruction (RAI) was recorded.
Time frame: Baseline, Week 2, and Week 4
| Milestone | Current Anti-asthma Therapy at a Fixed Dose | Placebo | FF 100 µg OD | FF/VI 100/25 µg OD |
|---|---|---|---|---|
| Started | 0 | 203 | 205 | 201 |
| Completed | 0 | 151 | 185 | 179 |
| Not completed | 0 | 52 | 20 | 22 |
| Withdrew: Adverse event | 0 | 1 | 0 | 2 |
| Withdrew: Lack of efficacy | 0 | 32 | 6 | 7 |
| Withdrew: Protocol violation | 0 | 7 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 2 |
| Withdrew: Physician decision | 0 | 6 | 7 | 6 |
| Withdrew: Withdrawal by subject | 0 | 6 | 6 | 3 |
Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 is defined as the clinic visit (pre-bronchodilator and pre-dose) FEV1measurement taken at the clinic visit while still on-treatment. Pre-dose and pre-rescue albuterol/salbutamol trough FEV1 was measured electronically by spirometry in the evening at the Baseline through Week 12 clinic visits. The highest of 3 technically acceptable measurements was recorded. Baseline was the pre-dose value obtained at Visit 3. Change from Baseline was calculated as the Week 12 value minus the Baseline value. The analysis was performed using an Analysis of Covariance (ANCOVA) model with covariates of Baseline trough FEV1, region, sex, age, and treatment group. The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement at scheduled clinic visits was used to impute the missing m
| Liters | Placebo | FF 100 µg OD | FF/VI 100/25 µg OD |
|---|---|---|---|
| Mean Change From Baseline in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at Week 12 | 0.196 ± 0.0310 | 0.332 ± 0.0302 | 0.368 ± 0.0304 |
Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Serial FEV1 measurements were taken electronically by spirometry at the Baseline and Week 12 clinic visits. Weighted mean was calculated using the 24-hour serial FEV1 measurements that included the pre-dose assessment (within 30 minutes prior to dosing at Baseline and within 5 minutes prior to dosing at Week 12) and post-dose assessments after 5, 15, and 30 minutes and 1, 2, 3, 4, 5, 12, 16, 20, 23, and 24 hours. At each time point, the highest of 3 technically acceptable measurements was recorded. Baseline was the value obtained at Visit 3. Change from Baseline was calculated as the average Week 12 FEV1 value minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline FEV1, region, sex, age, and treatment group.
| Liters | Placebo | FF 100 µg OD | FF/VI 100/25 µg OD |
|---|---|---|---|
| Change From Baseline in Weighted Mean Serial FEV1 Over 0-24 Hours Post-dose at Week 12 | 0.212 ± 0.0456 | 0.398 ± 0.0432 | 0.513 ± 0.0430 |
The number of inhalations of rescue albuterol/salbutamol inhalation aerosol used during the day and night was recorded by the participants in a daily electronic diary (eDiary). A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered to be rescue free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 12-week Treatment Period minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.
| Percentage of rescue-free 24-hr periods | Placebo | FF 100 µg OD | FF/VI 100/25 µg OD |
|---|---|---|---|
| Mean Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 12-week Treatment Period | 17.8 ± 2.26 | 26.5 ± 2.25 | 37.1 ± 2.26 |
Asthma symptoms were recorded in a daily eDairy by the participants every day in the morning and evening before taking any rescue or study medication and before the peak expiratory flow measurement. A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered to be symptom free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 12-week Treatment Period minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.
| Percentage of symptom-free 24-hr periods | Placebo | FF 100 µg OD | FF/VI 100/25 µg OD |
|---|---|---|---|
| Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 12-week Treatment Period | 14.6 ± 2.15 | 20.4 ± 2.13 | 32.5 ± 2.14 |
The AQLQ is a disease-specific, self-administered quality of life questionnaire used to evaluate the impact of asthma treatments on the quality of life of asthma sufferers. The AQLQ for 12 years and older (AQLQ \[+12\]) is a modified version of the AQLQ for use in asthma patients between the age of 12 and 70. The AQLQ contains 32 items in 4 domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), and environmental stimuli (4 items). For the 32 items on the questionnaire, the response format consists of a seven-point scale, where a value of 1 indicates "total impairment" and a value of 7 indicates "no impairment." The AQLQ total score is defined as the average of the scores from all 32 questions; thus, the total score ranges from 1 (indicates "total impairment") to 7 (indicates "no impairment"). Baseline was the total score obtained at Visit 3. Change from Baseline was calculated as the total score at Week 12 minus the total score at Baseline.
| Score on a scale | Placebo | FF 100 µg OD | FF/VI 100/25 µg OD |
|---|---|---|---|
| Change From Baseline in the Total Asthma Quality of Life Questionnaire (AQLQ) (+12) Score at Week 12/Early Withdrawal | 0.61 ± 0.061 | 0.76 ± 0.055 | 0.91 ± 0.055 |
The number of participants whose primary reason for withdrawal was lack of efficacy was analyzed.
| participants | Placebo | FF 100 µg OD | FF/VI 100/25 µg OD |
|---|---|---|---|
| Number of Participants Who Withdrew Due to Lack of Efficacy During the 12-week Treatment Period | 32 | 6 | 7 |
Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Serial FEV1 measurements were taken electronically by spirometry at Randomization. Serial FEV1 measurements after 5, 15, and 30 minutes and 1 hour post-dose were assessed. At each time point, the highest of 3 technically acceptable measurements was recorded. The analysis was performed using a repeated measures model adjusted for baseline, region, sex, age, treatment group, and planned time points.
| Liters | Placebo | FF 100 µg OD | FF/VI 100/25 µg OD |
|---|---|---|---|
| 5 Minutes, n=117, 112, 117 | 2.489 ± 0.0308 | 2.493 ± 0.0314 | 2.484 ± 0.0308 |
| 15 Minutes, n=118, 115, 117 | 2.491 ± 0.0336 | 2.529 ± 0.0342 | 2.566 ± 0.0336 |
| 30 Minutes, n=118, 116, 118 | 2.532 ± 0.0354 | 2.552 ± 0.0359 | 2.596 ± 0.0354 |
| 1 Hour, n=119, 116, 119 | 2.552 ± 0.0344 | 2.571 ± 0.0350 | 2.674 ± 0.0344 |
Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. 12-hour post-dose FEV1 measurements were taken electronically by spirometry at the Week 12 clinic visit. The highest of 3 technically acceptable measurements was recorded. The analysis was performed using an ANCOVA model with covariates of Baseline FEV1, region, sex, age, and treatment group.
| Liters | Placebo | FF 100 µg OD | FF/VI 100/25 µg OD |
|---|---|---|---|
| Clinic Visit 12-hour Post-dose FEV1 at Week 12 | 2.462 ± 0.0502 | 2.674 ± 0.0475 | 2.830 ± 0.0468 |
Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Serial FEV1 measurements were taken electronically by spirometry at Baseline. Weighted mean was calculated using the 24-hour serial FEV1 measurements that included the pre-dose assessment (within 30 minutes prior to dosing) and post-dose assessments after 5, 15, and 30 minutes and 1, 2, 3, 4, 5, 12, 16, 20, 23, and 24 hours. At each time point, the highest of 3 technically acceptable measurements were recorded. Baseline was the value obtained at Visit 3.
| Liters | Placebo | FF 100 µg OD | FF/VI 100/25 µg OD |
|---|---|---|---|
| Weighted Mean Serial FEV1 Over 0-24 Hours Post-dose at Baseline | 2.543 ± 0.8494 | 2.552 ± 0.7527 | 2.709 ± 0.8153 |
Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Serial FEV1 measurements were taken electronically by spirometry at the Baseline and Week 12 clinic visits. Weighted mean serial FEV1 over 0-4 hours was calculated using the serial FEV1 measurements that included the pre-dose assessment (within 30 minutes prior to dosing at Baseline and within 5 minutes prior to dosing at Week 12) and post-dose assessments after 5, 15, and 30 minutes and 1, 2, 3, and 4 hours. At each time point, the highest of 3 technically acceptable measurements were recorded. Baseline was the value obtained at Visit 3.
| Liters | Placebo | FF 100 µg OD | FF/VI 100/25 µg OD |
|---|---|---|---|
| Baseline, n=120, 115, 119 | 2.563 ± 0.8194 | 2.522 ± 0.7479 | 2.693 ± 0.7626 |
| Week 12, n=96, 105, 109 | 2.636 ± 0.8519 | 2.657 ± 0.7912 | 2.894 ± 0.8383 |
Bronchodilator effect is defined as an increase of FEV1 (defined as the maximal amount of air that can be forcefully exhaled in one second) from Baseline of both 12% and 200 milliliters (mL) during 24 hours, which was evaluated using the serial FEV1 measurements at Baseline (Visit 3).
| participants | Placebo | FF 100 µg OD | FF/VI 100/25 µg OD |
|---|---|---|---|
| Number of Participants With Bronchodilator Effect | 73 (0 to 272.0) | 77 (0 to 270.0) | 97 (0 to 62.0) |
Peak Expiratory Flow (PEF) is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each morning prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily AM PEF over the 12-week treatment period (at Week 12) minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.
| Liters per minute | Placebo | FF 100 µg OD | FF/VI 100/25 µg OD |
|---|---|---|---|
| Mean Change From Baseline in Daily Morning (AM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period | -0.4 ± 2.42 | 18.3 ± 2.41 | 32.9 ± 2.42 |
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily PM PEF over the 12-week treatment period (at Week 12) minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age, and treatment group.
| Liters per minute | Placebo | FF 100 µg OD | FF/VI 100/25 µg OD |
|---|---|---|---|
| Mean Change From Baseline in Daily Evening (PM) PEF Averaged Over the 12-week Treatment Period | -1.8 ± 2.36 | 14.1 ± 2.34 | 26.4 ± 2.35 |
The ACT is a 5-item questionnaire developed as a measure of the participant's asthma control. Questions are designed to be self-completed by the participant and include the following: In the past 4 weeks, "How much of the time did your asthma keep you from getting as much done at work, school or at home?", "How often have you had shortness of breath?", "How often did your asthma symptoms wake you up at night or earlier than usual in the morning?", "How often have you used your rescue inhaler or nebulizer medication (such as albuterol)?" and "How would you rate your asthma control"? The ACT total score is defined as the sum of the scores from all 5 questions, provided all questions have been answered; thus, the total score ranges from 5 (poor control of asthma) to 25 (complete control of asthma). A score of 20 or higher indicates well-controlled asthma. Change from Baseline was calculated as the total score at Week 12/Early Withdrawal minus the total score at Baseline.
| Scores on a scale | Placebo | FF 100 µg OD | FF/VI 100/25 µg OD |
|---|---|---|---|
| Change From Baseline in the Asthma Control Test (ACT) Score at Week 12 | 2.5 ± 0.26 | 3.8 ± 0.23 | 4.4 ± 0.23 |
At the end of Week 4, Week 8, and Week 12/Early Withdrawal, the Global Assessment of Change Questionnaire that assesses changes in asthma symptoms (AS) and rescue medication use (RMU) was completed by the participants. The number of participants who chose the following answers to the questionnaire were determined: much better, somewhat better, a little better, the same, a little worse, somewhat worse, much worse (to assess the changes in asthma symptom); much less often , somewhat less often , a little less often , the same , a little more often , somewhat more often , much more often (to assess the changes in the frequency of rescue medication use).
| participants | Placebo | FF 100 µg OD | FF/VI 100/25 µg OD |
|---|---|---|---|
| Week 4, AS - Much better, n=174, 198, 191 | 34 | 47 | 65 |
| Week 4, AS - Somewhat better, n=174, 198, 191 | 45 | 65 | 61 |
| Week 4, AS - A little better, n=174, 198, 191 | 42 | 47 | 37 |
| Week 4, AS - The same, n=174, 198, 191 | 33 | 29 | 23 |
| Week 4, AS - A little worse, n=174, 198, 191 | 6 | 10 | 3 |
| Week 4, AS - Somewhat worse, n=174, 198, 191 | 8 | 0 | 2 |
| Week 4, AS - Much worse, n=174, 198, 191 | 6 | 0 | 0 |
| Week 4, RMU - Much less often, n=174, 198, 191 | 39 | 59 | 75 |
| Week 4, RMU - Somewhat less often, n=174, 198, 191 | 40 | 48 | 51 |
| Week 4, RMU - A little less often, n=174, 198, 191 | 35 | 49 | 32 |
| Week 4, RMU - The same, n=174, 198, 191 | 31 | 33 | 28 |
| Week 4, RMU - A little more often, n=174, 198, 191 | 13 | 6 | 4 |
| Week 4, RMU - Somewhat more often, n=174, 198, 191 | 11 | 3 | 1 |
| Week 4, RMU - Much more often, n=174, 198, 191 | 5 | 0 | 0 |
| Week 8, AS - Much better, n=159, 192, 184 | 36 | 54 | 69 |
| Week 8, AS - Somewhat better, n=159, 192, 184 | 44 | 60 | 63 |
| Week 8, AS - A little better, n=159, 192, 184 | 38 | 40 | 22 |
| Week 8, AS - The same, n=159, 192, 184 | 29 | 33 | 24 |
| Week 8, AS - A little worse, n=159, 192, 184 | 7 | 5 | 3 |
| Week 8, AS - Somewhat worse, n=159, 192, 184 | 4 | 0 | 2 |
| Week 8, AS - Much worse, n=159, 192, 184 | 1 | 0 | 1 |
| Week 8, RMU - Much less often, n=159, 191, 184 | 37 | 65 | 86 |
| Week 8, RMU - Somewhat less often, n=159, 191, 184 | 32 | 48 | 43 |
| Week 8, RMU - A little less often, n=159, 191, 184 | 37 | 34 | 25 |
| Week 8, RMU - The same, n=159, 191, 184 | 36 | 39 | 23 |
| Week 8, RMU - A little more often, n=159, 191, 184 | 12 | 1 | 5 |
| Week 8, RMU - Somewhat more often, n=159, 191, 184 | 4 | 4 | 0 |
| Week 8, RMU - Much more often, n=159, 191, 184 | 1 | 0 | 2 |
| Week 12, AS - Much better, n=152, 187, 182 | 38 | 66 | 86 |
| Week 12, AS - Somewhat better, n=152, 187, 182 | 37 | 49 | 52 |
| Week 12, AS - A little better, n=152, 187, 182 | 29 | 35 | 13 |
| Week 12, AS - The same, n=152, 187, 182 | 29 | 30 | 23 |
| Week 12, AS - A little worse, n=152, 187, 182 | 9 | 7 | 7 |
| Week 12, AS - Somewhat worse, n=152, 187, 182 | 6 | 0 | 1 |
| Week 12, AS - Much worse, n=152, 187, 182 | 4 | 0 | 0 |
| Week 12, RMU - Much less often, n=150, 187, 182 | 42 | 76 | 89 |
| Week 12, RMU -Somewhat less often, n=150, 187, 182 | 32 | 46 | 43 |
| Week 12, RMU -A little less often, n=150, 187, 182 | 24 | 25 | 21 |
| Week 12, RMU - The same, n=150, 187, 182 | 34 | 32 | 23 |
| Week 12, RMU -A little more often, n=150, 187, 182 | 12 | 6 | 5 |
| Week 12, RMU -Somewhat more often, n=150, 187, 182 | 3 | 1 | 1 |
| Week 12, RMU - Much more often, n=150, 187, 182 | 3 | 1 | 0 |
All unscheduled asthma-related visits to a physician's office, visits to urgent care, visits to the emergency department, and hospitalizations (ICU=intensive care unit; GW=general ward) associated with severe asthma exacerbations or other asthma-related healthcare were recorded.
| Number of visits | Placebo | FF 100 µg OD | FF/VI 100/25 µg OD |
|---|---|---|---|
| Number of Home Visits (Day) | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| Number of Home Visits (Night) | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| Number of Physician Office/Practice Visits | 0.0 ± 0.24 | 0.0 ± 0.39 | 0.0 ± 0.10 |
| Number of Urgent Care/Outpatient Clinic Visits | 0.0 ± 0.07 | 0.0 ± 0.07 | 0.0 ± 0.00 |
| Number of Emergency Room Visits | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| Number of Inpatient Hospitalization Days (ICU) | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| Number of Inpatient Hospitalization (GW) Days | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
Participants were given a demonstration of correct inhaler use (using placebo inhalers), and the participants' competence to correctly use the demonstration inhaler was then assessed.
| participants | Placebo | FF 100 µg OD | FF/VI 100/25 µg OD |
|---|---|---|---|
| BL: Used Inhaler Correctly, n=203, 205, 201 | 194 | 196 | 188 |
| BL: Used Inhaler Incorrectly, n=203, 205, 201 | 9 | 9 | 13 |
| W2: Used Inhaler Correctly, n=190, 203, 200 | 190 | 203 | 200 |
| W2: Used Inhaler Incorrectly, n=190, 203, 200 | 0 | 0 | 0 |
| W4: Used Inhaler Correctly, n=175, 199, 195 | 175 | 199 | 195 |
| W4: Used Inhaler Incorrectly, n=175, 199, 195 | 0 | 0 | 0 |
Participants were given a demonstration of correct inhaler use (using placebo inhalers), and the participants' competence to correctly use the demonstration inhaler was then assessed based on 3 steps: open the device, inhale the dose, and close the device. If the participants did not perform the maneuvers correctly, the step of the inhaler use that was performed incorrectly by the participants was recorded. The entire procedure was demonstrated once again. and the number of times that the participants required additional instruction (RAI) was recorded.
| participants | Placebo | FF 100 µg OD | FF/VI 100/25 µg OD |
|---|---|---|---|
| BL: Opened the Device Incorrectly, n= 9, 9, 13 | 8 | 4 | 6 |
| BL: Inhaled the Dose Incorrectly, n= 9, 9, 13 | 1 | 5 | 6 |
| BL: Closed the Device Incorrectly, n= 9, 9, 13 | 1 | 0 | 1 |
| BL: RAI once, n= 9, 9, 13 | 9 | 5 | 8 |
| BL: RAI 2 Times, n= 9, 9, 13 | 0 | 4 | 4 |
| BL: RAI 3 Times, n= 9, 9, 13 | 0 | 0 | 1 |
| BL: RAI >3 Times, n= 9, 9, 13 | 0 | 0 | 0 |
| W2: Opened the Device Incorrectly, n= 0, 0, 0 | NA | NA | NA |
| W2: Inhaled the Dose Incorrectly, n= 0, 0, 0 | NA | NA | NA |
| W2: Closed the Device Incorrectly, n= 0, 0, 0 | NA | NA | NA |
| W2: RAI once, n= 0, 0, 0 | NA | NA | NA |
| W2: RAI 2 Times, n= 0, 0, 0, | NA | NA | NA |
| W2: RAI 3 Times, n= 0, 0, 0 | NA | NA | NA |
| W4: Opened the Device Incorrectly, n= 0, 0, 0 | NA | NA | NA |
| W4: Inhaled the Dose Incorrectly, n= 0, 0, 0 | NA | NA | NA |
| W4: Closed the Device Incorrectly, n= 0, 0, 0 | NA | NA | NA |
| W4: RAI once, n= 0, 0, 0 | NA | NA | NA |
| W4: RAI 2 Times, n= 0, 0, 0 | NA | NA | NA |
| W4: RAI 3 Times, n= 0, 0, 0 | NA | NA | NA |
| W4: RAI >3 Times, n= 0, 0, 0 | NA | NA | NA |
Collected over Serious Adverse Events (SAEs) and non-serious AEs were collected from the first dose of study medication up to Week 12/Early Withdrawal.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/203 (0%) | 22/203 (10.8%) |
| FF 100 µg OD | — | 1/205 (0.5%) | 20/205 (9.8%) |
| FF/VI 100/25 µg OD | — | 0/201 (0%) | 29/201 (14.4%) |
| Event | Placebo | FF 100 µg OD | FF/VI 100/25 µg OD |
|---|---|---|---|
| PancreatitisGastrointestinal disorders | 0/203 | 1/205 | 0/201 |
| Event | Placebo | FF 100 µg OD | FF/VI 100/25 µg OD |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 15/203 | 14/205 | 20/201 |
| HeadacheNervous system disorders | 8/203 | 9/205 | 10/201 |
| Age, Continuous(Years) | Placebo | FF 100 µg OD | FF/VI 100/25 µg OD | Total |
|---|---|---|---|---|
| Mean | 38.1 ± 16.49 | 40.4 ± 16.78 | 40.7 ± 16.38 | 39.7 ± 16.56 |
| Sex: Female, Male(Participants) | Placebo | FF 100 µg OD | FF/VI 100/25 µg OD | Total |
|---|---|---|---|---|
| Female | 111 | 126 | 116 | 353 |
| Male | 92 | 79 | 85 | 256 |
| Race/Ethnicity, Customized(participants) | Placebo | FF 100 µg OD | FF/VI 100/25 µg OD | Total |
|---|---|---|---|---|
| African American/African Heritage | 14 | 16 | 13 | 43 |
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian - Japanese Heritage | 19 | 16 | 15 | 50 |
| Asian - South East Asian Heritage | 0 | 0 | 1 | 1 |
| White - Arabic/North African Heritage | 0 | 1 | 0 | 1 |
| White - White/Caucasian/European Heritage | 169 | 170 | 172 | 511 |
| Mixed Race | 1 | 1 | 0 | 2 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Aug 2010, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2013, 1 year 9 months after primary completion. A results delay was requested in May 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.